Cogent Price To Sales Ratio from 2010 to 2025
| COGT Stock | USD 6.71 0.28 4.01% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 18.18 | Current Value 35.83 | Quarterly Volatility 34.62521885 |
Check Cogent Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cogent Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 4.8 M or Selling General Administrative of 41.5 M, as well as many indicators such as Price To Sales Ratio of 35.83, Dividend Yield of 0.0 or PTB Ratio of 3.48. Cogent financial statements analysis is a perfect complement when working with Cogent Biosciences Valuation or Volatility modules.
Cogent | Price To Sales Ratio |
Latest Cogent Biosciences' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Cogent Biosciences over the last few years. Price to Sales Ratio is figured by comparing Cogent Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cogent Biosciences sales, a figure that is much harder to manipulate than other Cogent Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Cogent Biosciences' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cogent Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 1,321 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Cogent Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 45.79 | |
| Geometric Mean | 29.42 | |
| Coefficient Of Variation | 75.62 | |
| Mean Deviation | 31.02 | |
| Median | 39.32 | |
| Standard Deviation | 34.63 | |
| Sample Variance | 1,199 | |
| Range | 86.1676 | |
| R-Value | (0.83) | |
| Mean Square Error | 403.02 | |
| R-Squared | 0.69 | |
| Significance | 0.000074 | |
| Slope | (6.02) | |
| Total Sum of Squares | 17,984 |
Cogent Price To Sales Ratio History
About Cogent Biosciences Financial Statements
Cogent Biosciences shareholders use historical fundamental indicators, such as Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Cogent Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Cogent Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cogent Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 18.18 | 35.83 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.